$99.7 Million is the total value of Burrage Capital Management LLC's 22 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 40.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BCRX | BIOCRYST PHARMACEUTICALS INC | $13,674,000 | +55.5% | 864,916 | 0.0% | 13.71% | +92.3% | |
| NTLA | INTELLIA THERAPEUTICS INC | $10,303,000 | +101.7% | 63,634 | 0.0% | 10.33% | +149.6% | |
| EPZM | Buy | EPIZYME INC | $6,954,000 | +41.4% | 836,802 | +48.2% | 6.97% | +75.0% |
| EPIX | ESSA PHARMA INC | $6,784,000 | -1.7% | 237,442 | 0.0% | 6.80% | +21.7% | |
| NEO | NEOGENOMICS INC | $6,682,000 | -6.3% | 147,921 | 0.0% | 6.70% | +15.9% | |
| MEIP | MEI PHARMA INC | $6,644,000 | -16.9% | 2,331,313 | 0.0% | 6.66% | +2.8% | |
| CRNX | Buy | CRINETICS PHARMACEUTICALS IN | $5,554,000 | +33.4% | 294,620 | +8.2% | 5.57% | +65.1% |
| CYTK | CYTOKINETICS INC | $4,842,000 | -14.9% | 244,673 | 0.0% | 4.86% | +5.3% | |
| FOLD | New | AMICUS THERAPEUTICS INC | $4,820,000 | – | 500,000 | +100.0% | 4.83% | – |
| HRMY | HARMONY BIOSCIENCES HLDGS IN | $4,234,000 | -14.6% | 150,000 | 0.0% | 4.24% | +5.7% | |
| INZY | Buy | INOZYME PHARMA INC | $4,132,000 | +23.1% | 242,517 | +43.1% | 4.14% | +52.3% |
| YMAB | Y-MABS THERAPEUTICS INC | $3,869,000 | +11.8% | 114,454 | 0.0% | 3.88% | +38.3% | |
| MIRM | MIRUM PHARMACEUTICALS INC | $3,559,000 | -12.8% | 205,866 | 0.0% | 3.57% | +7.9% | |
| ADCT | ADC THERAPEUTICS SA | $3,041,000 | -0.2% | 124,875 | 0.0% | 3.05% | +23.4% | |
| VSTM | New | VERASTEM INC | $2,872,000 | – | 705,585 | +100.0% | 2.88% | – |
| MRUS | MERUS N V | $2,753,000 | +0.8% | 130,683 | 0.0% | 2.76% | +24.8% | |
| GERN | GERON CORP | $2,697,000 | -10.8% | 1,912,673 | 0.0% | 2.70% | +10.4% | |
| AVRO | AVROBIO INC | $2,177,000 | -30.0% | 244,920 | 0.0% | 2.18% | -13.3% | |
| RVMD | New | REVOLUTION MEDICINES INC | $1,587,000 | – | 50,000 | +100.0% | 1.59% | – |
| BDTX | BLACK DIAMOND THERAPEUTICS I | $1,346,000 | -49.8% | 110,447 | 0.0% | 1.35% | -37.8% | |
| GTHX | Sell | G1 THERAPEUTICS INC | $1,047,000 | -63.0% | 47,708 | -59.5% | 1.05% | -54.2% |
| TPTX | Sell | TURNING POINT THERAPEUTICS I | $169,000 | -97.5% | 2,164 | -97.0% | 0.17% | -96.9% |
| Exit | INTELLIA THERAPEUTICS INC | $0 | – | -630 | -100.0% | -0.04% | – | |
| Exit | TURNING POINT THERAPEUTICS I | $0 | – | -700 | -100.0% | -0.70% | – | |
| APLS | Exit | APELLIS PHARMACEUTICALS INC | $0 | – | -80,727 | -100.0% | -2.81% | – |
| TCDA | Exit | TRICIDA INC | $0 | – | -658,877 | -100.0% | -2.82% | – |
| FULC | Exit | FULCRUM THERAPEUTICS INC | $0 | – | -319,819 | -100.0% | -3.05% | – |
| CARA | Exit | CARA THERAPEUTICS INC | $0 | – | -180,000 | -100.0% | -3.17% | – |
| PTCT | Exit | PTC THERAPEUTICS INC | $0 | – | -160,372 | -100.0% | -6.15% | – |
| PLX | Exit | PROTALIX BIOTHERAPEUTICS INC | $0 | – | -2,125,585 | -100.0% | -7.68% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| EPIZYME INC COM | 7 | Q2 2021 | 15.9% |
| NeoGenomics Inc | 7 | Q2 2021 | 8.7% |
| OrthoPediatrics Corp | 7 | Q2 2021 | 7.3% |
| Y-MABS THERAPEUTICS INC COM | 7 | Q2 2021 | 4.3% |
| CRINETICS PHARMACEUTICALS INC COM | 7 | Q2 2021 | 5.6% |
| G1 THERAPEUTICS INC COM | 7 | Q2 2021 | 7.3% |
| PTC THERAPEUTICS INC COM | 6 | Q1 2021 | 8.0% |
| CYTOKINETICS INC COM NEW | 6 | Q2 2021 | 4.9% |
| TURNING PT THERAPEUTICS INC COM | 6 | Q2 2021 | 6.7% |
| APELLIS PHARMACEUTICALS INC COM | 6 | Q1 2021 | 3.5% |
View Burrage Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Protalix BioTherapeutics, Inc.Sold out | July 30, 2021 | 0 | 0.0% |
| IVERIC bio, Inc. | February 14, 2020 | 10 | 3.4% |
View Burrage Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2021-11-15 |
| 13F-HR | 2021-08-16 |
| SC 13G/A | 2021-07-30 |
| 13F-HR | 2021-05-17 |
| 13F-HR | 2021-02-12 |
| SC 13G | 2021-02-12 |
| 13F-HR | 2020-11-13 |
| 13F-HR | 2020-08-14 |
| 13F-HR | 2020-05-14 |
| 13F-HR | 2020-02-14 |
View Burrage Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.